
|Videos|September 1, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Advertisement
Articles in this issue
about 8 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCabout 8 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































